MARKET

CTIC

CTIC

CTi Biopharma
NASDAQ

Real-time Quotes | Nasdaq Last Sale

0.9200
+0.0345
+3.90%
Closed 16:00 09/20 EDT
OPEN
0.8800
PREV CLOSE
0.8855
HIGH
0.9200
LOW
0.8600
VOLUME
165.51K
TURNOVER
--
52 WEEK HIGH
2.300
52 WEEK LOW
0.6001
MARKET CAP
53.34M
P/E (TTM)
-1.4918
1D
5D
1M
3M
1Y
5Y

Buy or sell shares of CTIC and other stocks commission-free!

Open a Webull account and fund it to get a free stock

Analyst Rating

Based on 2 analysts

Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

EPS

CTIC News

  • CTI BioPharma Reports Second Quarter 2019 Financial Results
  • PR Newswire.08/01 21:05
  • CTI BioPharma Q2 EPS $(0.19), Inline, Sales $400K Down From $613K YoY
  • Benzinga.08/01 20:13
  • CTI BioPharma Announces Outcome From End-of-Phase-2a Meeting With U.S. Food and Drug Administration (FDA) Regarding Pacritinib for Treatment of Myelofibrosis
  • PR Newswire.07/18 12:00
  • CTI BioPharma to Present at the JMP Securities Life Sciences Conference on Thursday, Jun. 20
  • PR Newswire.06/13 12:00

More

Industry

Biotechnology & Medical Research
+0.62%
Pharmaceuticals & Medical Research
+0.95%

Hot Stocks

Name
Price
%Change

About CTIC

CTI BioPharma Corp. is a biopharmaceutical company focused on the acquisition, development and commercialization of targeted therapies covering a spectrum of blood-related cancers to patients and healthcare providers. The Company is primarily focused on commercializing PIXUVRI in select countries in the European Union, for multiply relapsed or refractory aggressive B-cell non-Hodgkin lymphoma (NHL). It is also engaged in evaluating pacritinib for the treatment of adult patients with myelofibrosis. Its earlier stage product candidate, tosedostat, is an oral, once-daily aminopeptidase inhibitor that has demonstrated responses in patients with acute myeloid leukemia (AML). It also evaluates its pipeline candidate paclitaxel poliglumex (Opaxio), which targets solid tumors. It is evaluating Opaxio through cooperative group sponsored trials and investigator-sponsored trials (IST), such as the ongoing maintenance therapy trial in patients with ovarian cancer.
More

Webull offers CTI BioPharma Corp (CTIC) stock price, real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, stock news, and many more online research tools to help you make informed decisions.